United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-12 EDT			5-day change	1st Jan Change
532.82 ^USD	-2.18%		+9.85%	+9.35%

03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI
03-09	BETA Technologies Participates In FAA?s eVTOL Integration Pilot Program Across 10 States	CI

Transcript : United Therapeutics Corporation Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10

Published on 03/11/2025 at 10:00 am EDT

S&P Capital IQ

Presenter Speech
Roanna Clarissa Ruiz (Analysts)

Great. Welcome, everyone. My name is Roanna Ruiz. I'm one of the senior biotech analysts here at Leerink. And I just want to welcome you to our Global

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about United Therapeutics Corporation

03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI
03-09	BETA Technologies Participates In FAA?s eVTOL Integration Pilot Program Across 10 States	CI
03-09	United Therapeutics Corporation Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 01:00 PM
03-09	United Therapeutics Corporation authorizes a Buyback Plan.	CI
03-09	United Therapeutics Corporation announces an Equity Buyback for $2,000 million worth of its shares.	CI
03-09	United Therapeutics unveils $2 bln buyback plan, launches $1.5 bln accelerated repurchase	RE
03-05	United Therapeutics Insider Sold Shares Worth $4,744,467, According to a Recent SEC Filing	MT
03-05	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
03-05	UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating	MT
03-02	United Therapeutics Corporation - Special Call
03-02	United Therapeutics Corporation Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM
03-02	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy	CI
03-02	United Therapeutics Corporation announces ralinepag achieved 55% reduction in risk of clinical worsening in pivotal pulmonary arterial hypertension study, delivering exceptional, highly statistically significant efficacy	RE
03-02	United Therapeutics Says Ralinepag Cut Risk of Clinical Worsening by 55% in Phase 3 Study	MT
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE